Account
Case Study
01.01.2023
The impact of international reference pricing

Our client was seeking market authorisation for one indication and were expected a secondary indicat...

Read more
Case Study
01.01.2023
Developing a multi-indication budget impact model

Our client had in-licenced a hospital drug that they were seeking to launch in the EU, following a r...

Read more
Case Study
01.01.2023
Support with the launch of an ultra-orphan drug

Our client was struggling to understand the value of their product (a single-use treatment for an ul...

Read more
News
15.12.2022
PMA Insights: Week 50

We summarise four handpicked articles from pharmaceutical, pricing and market access that are worth ...

Read more
Webinar
08.12.2022
Are you ready for the new EU HTA in 2025?

Webinar: Our experts discuss the latest news and updates on the EU HTA process, including the Joint ...

Read more
News
16.11.2022
PMA Insights: Week 46 SPECIAL EDITION ISPOR 2022 R...

We summarise the ISPOR Europe 2022 conference including plenary sessions on HTA, patient-centered re...

Read more
Publications
09.11.2022
ISPOR 2022 Plenary Session 3 - Integrating Data

Our experts provide a detailed summary of Plenary Session 2 at ISPOR 2022 on innovative methods for ...

Read more
Publications
08.11.2022
ISPOR 2022 Plenary Session 2 - Real-World Research

Introduction Real World Data is being increasingly used across the globe to support medical-product ...

Read more
Publications
07.11.2022
ISPOR 2022 Plenary Session 1 - HTA and Regulation

Our experts provide a detailed summary of Plenary Session 1 at ISPOR 2022 on the Convergence of HTA ...

Read more
Insider Insights
04.11.2022
UK: NICE conditionally recommends digital cognitiv...

NICE guidance published today on digital health technologies suggest they can be used to help young ...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.